CMG-DIGITAL
25.4.2022 01:02:06 CEST | Business Wire | Press release
Global digital design and smart production agency CMG Digital is today relaunching as part of an ongoing evolution of its company brand.
The agency, based in Croatia, with a presence in the UK and the US, now has a new vision and is dedicating itself to putting humanity back into digital.
The acceleration of digital adoption during the pandemic brought many positives to the digital space, including investment, faster development, new services and virtual worlds. At the same time, it has also tackled issues around security, privacy, sustainability and inefficiencies.
More significantly, the acceleration of digital has seen a move towards automation and away from humanisation in digital.
The relaunched CMG Digital is the answer: an agency dedicated to supporting clients to ensure they can maximise success in digital within this context.
The new vision will also be accompanied by a new look. With the agency debuting a new logo, theme and tone of voice. The updated visual identity will represent the evolved brand values.
Putting humanity at the core of its company was an easy decision for the agency, which boasts two thirds of women holding the top management positions as well as women making up more than 55% of the overall employees. CMG Digital also boasts a mental health program called MindGiving to support the team: this includes yoga classes, managing stress workshops, meeting limits, no meeting Friday as well as additional health insurance.
Explaining the new vision, Ana Tolić, President of CMG said:
“We are both delighted and excited to enter this new era of CMG Digital history and focus on our mission of putting humanity back into digital.
“Over the course of the pandemic the lightning-fast adoption of digital meant the space quickly became inhuman and cold.
“We are an agency that recognises that we can’t replace the people's side of things with a platform, and that relationships are critical to success. We believe in focusing on B2H – Business to Human.”
The relaunch will also keep digital sustainability at the heart of the agency.
CMG Digital is known for setting the industry tone when it comes to sustainability. Historically, the agency standardised recycling long before it became compulsory. Now, it is leading the way once more and focussing on standardising its approach to digital sustainability.
As global-to-local experts, CMG Digital puts a strong focus on maximising content life through reuse, recycling and repurposing to reduce the digital waste of its clients.
This focus is allowing CMG Digital to spread its message, educate and upskilling clients and brands in digital sustainability as well as digital inclusivity.
CMG Digital hopes that its position as a leader in its field will enable it to set the tone and encourage other agencies to follow its example. The agency is a powerhouse in its industry, credited with delivering over 50,000 projects, working with more than 200 global brands and delivering to over 100 markets worldwide. Since 2001 it has been the digital custodian of some of the world’s most valuable brands across the globe, and today leading digital deployment for multinational corporations such as P&G, GSK, Novartis, ConvaTec, Cloetta, Edgewell and Rimac.
CMG Digital believes its relaunch will help it better achieve its overall goal of empowering brands to scale their global message to the local level with consistency and pace.
-ENDS-
View source version on businesswire.com: https://www.businesswire.com/news/home/20220424005009/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom